STOCK TITAN

ORIC Pharmaceuticals Q3 loss widens to $48.1M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

ORIC Pharmaceuticals, Inc. reported a third-quarter net loss of $48.1 million, compared with $32.6 million a year earlier. R&D expense was $43.4 million versus $28.8 million, and G&A expense was $8.2 million versus $7.9 million. Cash, cash equivalents and investments totaled $345.4 million at September 30, 2026; ORIC expects these funds to support its operating plan into the second half of 2028.

ORIC initiated Himalayas-1, a global Phase 3 trial of rinzimetostat plus darolutamide in post-abiraterone mCRPC. The trial is expected to enroll approximately 600 patients, with radiographic progression-free survival as its primary endpoint. Preliminary landmark rPFS estimates were 59% at 8, 9 and 10 months in the post-abiraterone cohort, and 71%, 59% and 59% at those months in the post-AR-inhibitor cohort.

In a Phase 1b study of enozertinib in first-line EGFR atypical NSCLC, ORIC reported investigator-confirmed systemic and intracranial ORRs of 84% and 70%. ORIC plans to initiate Redwood-1, a global Phase 3 trial, in the first half of 2027. Cancer Research UK will fund and sponsor early clinical development of ORIC-259; ORIC retains an option to reacquire rights after Phase 1/2 data.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Himalayas-1 Phase 3 began; expected enrollment is approximately 600 patients.

Negative

  • Moderate pointQuarterly net loss rose to $48.1 million from $32.6 million.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Cash, cash equivalents and investments $345.4 million As of September 30, 2026
Third-quarter net loss $48.1 million Three months ended September 30, 2026; compared with $32.6 million in 2025
Nine-month net loss $125.3 million Nine months ended September 30, 2026; compared with $99.0 million in 2025
Third-quarter R&D expenses $43.4 million Three months ended September 30, 2026; compared with $28.8 million in 2025
Systemic ORR 84% Investigator-confirmed response rate for enozertinib in the Phase 1b first-line EGFR atypical NSCLC study
Intracranial ORR 70% Investigator-confirmed response rate for enozertinib in the Phase 1b first-line EGFR atypical NSCLC study
Landmark rPFS 59% at each of 8, 9 and 10 months Preliminary post-abiraterone cohort; median follow-up of 7.8 months
Landmark rPFS 71%, 59% and 59% at 8, 9 and 10 months Preliminary post-AR-inhibitor cohort; median follow-up of 7.6 months
mCRPC medical
"metastatic castration-resistant prostate cancer (mCRPC)"
mCRPC stands for metastatic castration‑resistant prostate cancer, a form of prostate cancer that has spread beyond the prostate and keeps progressing despite treatments that lower male hormones. It matters to investors because this stage is harder to treat, drives demand for new therapies, and often involves large, expensive clinical trials and regulatory decisions that can strongly influence a drug maker’s future revenue and stock value—think of it as a stubborn problem that creates both medical need and commercial opportunity.
landmark rPFS medical
"landmark rPFS rates of 59% at each of 8, 9, and 10 months"
ORR medical
"84% confirmed systemic and 70% confirmed intracranial ORRs by investigator"
Objective Response Rate (ORR) is the percentage of patients in a clinical trial whose tumors shrink or disappear by a predefined amount after treatment. For investors, ORR is a quick, measurable signal of a therapy’s effectiveness—like early sales numbers for a new product—and strong ORR data can boost a drug’s commercial prospects and company valuation, while weak ORR can temper expectations.
blinded independent central review (BICR) medical
"blinded independent central review (BICR)"
A blinded independent central review (BICR) is a process in clinical trials where outside experts, who do not know which patients received the experimental treatment, centrally re-check key medical data (often images or test results) to confirm outcomes. Investors care because BICR reduces bias and disagreement in trial results—think of neutral referees reviewing game footage without team colors—so findings are more credible for regulators, partners and valuation decisions.
at-the-market (ATM) program financial
"raised from healthcare specialist funds during the first quarter under the ATM program"
An at-the-market (ATM) program is a way for a company to sell newly issued shares directly into the open market at the current trading price over time, rather than all at once. For investors it matters because it provides a flexible, ongoing source of capital but can dilute existing ownership and put steady selling pressure on a stock’s price—similar to a store quietly adding more items for sale at the posted price.
Periodic Safety Review (PSR) medical
"conducted a pre-planned biannual Periodic Safety Review (PSR)"
Net loss $48.1 million Compared with $32.6 million in 2025
Research and development expenses $43.4 million Compared with $28.8 million in 2025
General and administrative expenses $8.2 million Compared with $7.9 million in 2025
Net loss per share, basic and diluted $0.44 loss per share Compared with $0.33 loss per share in 2025
Guidance

Cash, cash equivalents and investments totaled $345.4 million as of September 30, 2026; ORIC expects them to fund its operating plan into the second half of 2028.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was ORIC's net loss in the third quarter of 2026?

ORIC's net loss was $48.1 million for the three months ended September 30, 2026, compared with $32.6 million a year earlier. For the nine months ended September 30, 2026, net loss was $125.3 million, versus $99.0 million in the prior-year period.

How many patients will the ORIC Himalayas-1 trial enroll, and what is its primary endpoint?

Himalayas-1 is expected to enroll approximately 600 patients, randomized 1:1 to receive rinzimetostat with darolutamide or physician’s choice of an AR inhibitor or docetaxel. Its primary endpoint is radiographic progression-free survival, and overall survival is the key secondary endpoint.

When is ORIC's Redwood-1 trial expected to start, and who will it enroll?

ORIC plans to initiate Redwood-1 in the first half of 2027. The trial is expected to enroll approximately 360 patients with EGFR PACC and L861X mutations, including patients with untreated brain metastases, and compare enozertinib with physician’s choice of osimertinib or afatinib.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001796280false00017962802026-11-162026-11-16

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

ORIC Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

 

 

Delaware

001-39269

47-1787157

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer
Identification No.)

 

240 E. Grand Ave, 2nd Floor

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

 

(650) 388-5600

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each

exchange on which registered

Common stock, par value $0.0001 per share

 

ORIC

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


 

Item 2.02 Results of Operations and Financial Condition.

On November 16, 2026, ORIC Pharmaceuticals, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release dated November 16, 2026

104

 

Cover Page Interactive Data File (embedded with the Inline XBRL document)

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

 

ORIC PHARMACEUTICALS, INC.

 

 

 

 

    Date: November 16, 2026

 

By:

/s/ Dominic Piscitelli

 

 

 

Dominic Piscitelli

Chief Financial Officer

 


img48504584_0.gif

Exhibit 99.1

 

ORIC® Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Operational and Rinzimetostat Program Updates

 

Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone, supported by a clinical trial collaboration and supply agreement with Bayer

 

Provided updated rinzimetostat combination data in post-abiraterone mCRPC and in post-AR inhibitor mCRPC, consisting of landmark rPFS estimates in both populations that remain consistent with competitor PRC2 inhibitor, and reconfirming a highly differentiated safety profile

 

Presented potential best-in-class enozertinib data at ESMO Congress 2026, including 84% systemic ORR and 70% CNS ORR, setting a new benchmark in 1L EGFR atypical NSCLC

 

Announced Redwood-1 global Phase 3 registrational trial in 1L EGFR atypical NSCLC, with initiation expected in 1H 2027

 

Cash and investments of approximately $345 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout from first Phase 3 trial for rinzimetostat

 

SOUTH SAN FRANCISCO and SAN DIEGO, CA – November 16, 2026 – ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today reported financial results and provided operational updates for the quarter ended September 30, 2026, and a rinzimetostat program update.

 

“Recent clinical data updates reinforce our confidence in the best-in-class potential of our late-stage portfolio, with rinzimetostat continuing to demonstrate an efficacy and safety profile in prostate cancer that is differentiated from current standards of care and the only other PRC2 inhibitor in Phase 3 development, and with enozertinib setting a new benchmark in 1L EGFR atypical NSCLC,” said Jacob M. Chacko, M.D., president and chief executive officer. “With the first Phase 3 trials either underway or planned across both programs and supported by a strong balance sheet, we are laser focused on execution in pursuit of our mission to Overcome Resistance In Cancer.”

 

Third Quarter 2026 and Other Recent Highlights

 

Rinzimetostat: a potent and selective allosteric inhibitor of PRC2

 

Second Half 2026 Program Update

 

The Company conducted a pre-planned biannual Periodic Safety Review (PSR) in October 2026 for the ongoing Phase 1b dose-optimization cohorts evaluating 400 mg QD rinzimetostat in

 


 

 

 

combination with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with abiraterone and in patients with mCRPC previously treated with an androgen receptor (AR) inhibitor. As of August 14, 2026, with a median follow-up of approximately 8 months, the safety profile across both patient populations was consistent with the prior March 2026 data disclosure; the vast majority of treatment-related adverse events (TRAEs) were Grade 1 in severity and consistent with PRC2 and AR inhibition. The most common TRAEs were fatigue (32%; 11% Grade 1, 16% Grade 2, and 5% Grade 3), diarrhea (24%; 19% Grade 1 and 5% Grade 2), and nausea (22%; 19% Grade 1 and 3% Grade 2), which are similar rates and grades to the March 2026 disclosure. Consistent with the prior disclosure, there were no Grade 4 or 5 adverse events attributed to rinzimetostat or darolutamide. These data continue to demonstrate a highly differentiated safety profile, with significantly lower frequency and severity of adverse events, nearly all Grade 1 or 2, and fewer treatment modifications than competitor regimens.

 

In parallel with the PSR, longer-term durability was also evaluated across both patient populations.

 

•
Post-abiraterone cohort: At the time of the previous data disclosure (March 6, 2026 data cutoff), of 18 efficacy-evaluable patients in this cohort, 7 remained on treatment without radiographic progression. As of the August 14, 2026 data cutoff, 2 of these 7 patients discontinued treatment due to radiographic progression (one at more than 13 months and one at more than 11 months), and 5 patients remained on treatment without radiographic progression, with the longest ongoing at nearly 17 months. While still preliminary with 28% of patients ongoing, landmark rPFS rates continue to demonstrate meaningful and durable clinical benefit for rinzimetostat in combination with darolutamide compared to competitor data and historical outcomes with approved therapies. With a median follow-up of 7.8 months, landmark rPFS rates of 59% at each of 8, 9, and 10 months are consistent with the competitor PRC2 inhibitor currently in multiple Phase 3 trials in prostate cancer (mevrometostat in combination with enzalutamide demonstrated estimated landmark rPFS rates of 63% at each of 8, 9, and 10 months in a post-abiraterone patient population). These rinzimetostat landmark rPFS rates are superior to reported outcomes for available standard-of-care therapies, including Xtandi®, Jevtana®, Taxotere®, and Pluvicto®. For reference, the estimated 10-month landmark rPFS for these approved therapies ranges from approximately 35% to 50%.

 

•
Post-AR inhibitor cohort: At the time of the previous data disclosure (March 6, 2026 data cutoff), of 19 efficacy-evaluable patients in this cohort, 8 remained on treatment without radiographic progression. As of the August 14, 2026 data cutoff, 2 of these 8 patients discontinued treatment (one at nearly 10 months due to clinical progression; one at more than 8 months due to an adverse event), and 6 patients remained on treatment without radiographic progression, 4 of whom are ongoing at between 12 to 16 months. While still preliminary with 32% of patients ongoing, landmark rPFS rates continue to demonstrate meaningful and durable clinical benefit for rinzimetostat in combination with darolutamide compared to competitor data and historical outcomes with approved therapies. With a median follow-up of 7.6 months, landmark rPFS rates of 71%, 59%, and 59% at 8, 9, and

 

 

 

 


 

 

 

10 months, respectively, are consistent with the competitor PRC2 inhibitor currently in multiple Phase 3 trials in prostate cancer (mevrometostat in combination with enzalutamide demonstrated estimated landmark rPFS rates of 58%, 54%, and 54% at 8, 9 and 10 months, respectively, in a post-AR inhibitor patient population). These rinzimetostat landmark rPFS rates are superior to reported outcomes for available standard-of-care therapies, including Zytiga®, Jevtana®, Taxotere®, and Pluvicto®. For reference, the estimated 10-month landmark rPFS for these approved therapies ranges from approximately 15% to 50%.

 

Additional Rinzimetostat Third Quarter 2026 and Other Recent Highlights

 

•
Finalized the trial protocol and initiated the Himalayas-1 global Phase 3 registrational trial following End-of-Phase 1 interactions with the FDA and other global health authorities. The Himalayas-1 trial is expected to enroll approximately 600 patients from over 250 sites in 25 countries, randomized 1:1 to receive 400 mg once daily oral rinzimetostat (with or without food) in combination with darolutamide versus physician’s choice of an AR inhibitor or docetaxel. The primary endpoint is radiographic progression-free survival and the key secondary endpoint is overall survival.
•
Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamide for Himalayas-1. Under the terms of the agreement, ORIC will conduct and sponsor the Himalayas-1 trial and Bayer will provide their AR inhibitor, NUBEQA® (darolutamide), at no cost for use in the trial in combination with rinzimetostat. This agreement does not grant Bayer any license, option, or other rights to rinzimetostat and ORIC retains full global development and commercial rights to rinzimetostat.
•
Presented preclinical data at ESMO Congress 2026 highlighting potential advantages of targeting PRC2 via EED over EZH2, including that prostate cancer cells that rapidly developed resistance to the EZH2 inhibitor mevrometostat acquired an EZH2 mutation against which the potency of the EED inhibitor rinzimetostat was maintained. Preclinical results, supported by translational data in mCRPC patient samples, showed rinzimetostat reinforces a luminal, AR-dependent state, restricts lineage plasticity and enhances sensitivity to AR inhibition.

 

Enozertinib: a brain-penetrant, selective inhibitor targeting EGFR atypical mutations and EGFR exon 20 insertion mutations

 

•
Presented potential best-in-class Phase 1b data at ESMO Congress 2026 in 1L NSCLC patients with EGFR atypical mutations. Despite enrolling patients with more than double the rate of baseline CNS disease as competitor datasets, including previously untreated CNS metastases, enozertinib demonstrated:
o
Meaningful systemic and compelling CNS responses: 84% confirmed systemic and 70% confirmed intracranial ORRs by investigator. These findings were supported by similar response rates utilizing the more stringent blinded independent central review (BICR), with a systemic ORR of 80% (RECIST 1.1) and an intracranial ORR of 67% (RANO-BM).

 

 

 

 


 

 

 

o
Promising early durability: while median PFS and duration of response data were immature as of the October 2026 data presentation cutoff date, a majority of patients remained on treatment and the 6-month landmark PFS of 88% compares favorably to reported benchmarks for currently used therapies and for late-stage investigational therapies.
o
A well-tolerated safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in no treatment-related discontinuations.
•
Supported by potential best-in-class data and based on End-of-Phase 1 interactions with the FDA, ORIC announced plans to initiate Redwood-1, a global Phase 3 registrational trial in 1L EGFR atypical NSCLC in 1H 2027. The Redwood-1 trial is expected to enroll approximately 360 patients with EGFR PACC and L861X mutations, including those with untreated brain metastases, randomized to receive 80 mg once daily oral enozertinib or physician’s choice of osimertinib or afatinib. Dual primary endpoints include ORR by BICR for potential accelerated approval as well as PFS by BICR for full approval. Key secondary endpoints include overall survival and intracranial ORR by BICR RANO-BM.

 

ORIC-259: a potent, selective, oral small molecule degrader of CIP2A mRNA

 

•
Announced agreement with Cancer Research UK (CRUK) to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy into clinical development. Under the agreement, CRUK will fully fund, sponsor, design, and execute CTA-enabling activities and early clinical development of ORIC-259 for patients with cancer. ORIC retains an option to reacquire rights to ORIC-259 following Phase 1/2 data, with CRUK eligible to receive downstream milestone payments and royalties.

 

 

Key Achievements and Anticipated Program Milestones:

 

•
Rinzimetostat in mCRPC:
✓
Announced combination dose optimization data with AR inhibitor
✓
Initiated first global Phase 3 registrational trial in post-abiraterone mCRPC
✓
2H 2026: Program update
•
Enozertinib in NSCLC:
✓
October 2026: 1L EGFR atypical monotherapy data presented at ESMO Congress 2026
−
1H 2027: Initiate first global Phase 3 registrational trial in 1L EGFR atypical
−
Mid-2027: 1L EGFR exon 20 monotherapy data and combination data with SC amivantamab and combination with chemotherapy

 

 

 

Third Quarter 2026 Financial Results

•
Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments totaled $345.4 million as of September 30, 2026, which includes $59.9 million in net

 

 

 

 


 

 

 

proceeds raised from healthcare specialist funds during the first quarter under the ATM (at-the-market) program. The company expects its cash and investments to fund the operating plan into 2H 2028.

 

•
R&D Expenses: Research and development (R&D) expenses were $43.4 million for the three months ended September 30, 2026, compared to $28.8 million for the three months ended September 30, 2025, an increase of $14.6 million. The increase was primarily due to an increase in external expenses related to the advancement of rinzimetostat, offset by lower enozertinib costs due to timing of manufacturing and clinical costs. For the nine months ended September 30, 2026, R&D expenses were $111.1 million, compared to $84.0 million for the nine months ended September 30, 2025, an increase of $27.1 million. The increase was primarily due to an increase in external expenses related to the advancement of rinzimetostat, offset by lower enozertinib costs due to timing of manufacturing and clinical costs as well as lower preclinical costs.

 

•
G&A Expenses: General and administrative (G&A) expenses were $8.2 million for the three months ended September 30, 2026, compared to $7.9 million for the three months ended September 30, 2025, an increase of $0.3 million. For the nine months ended September 30, 2026, G&A expenses were $25.4 million, compared to $24.5 million for the nine months ended September 30, 2025, an increase of $0.9 million. The increases were primarily due to higher professional services costs.

 

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR atypical and EGFR exon 20 insertion mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the continued clinical development of rinzimetostat and enozertinib; the potential advantages of rinzimetostat and enozertinib; clinical outcomes from studies of rinzimetostat and enozertinib, which may materially change as patient enrollment continues or more patient data become available; the development plans and timelines for rinzimetostat and enozertinib; plans underlying ORIC’s clinical trials and development; anticipated program milestones, including timing of program and data updates; the potential benefits of ORIC’s agreement with CRUK; the period over which ORIC estimates its existing cash and investments will be sufficient to fund its current operating plan; and statements by the company’s chief executive officer. Words such as “believes,” “anticipates,” “plans,” “expects,”

 

 

 

 


 

 

 

“intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and ORIC’s limited operating history; ORIC’s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC’s plans to develop and commercialize its product candidates; the potential for clinical trials of rinzimetostat, enozertinib or any other product candidates to differ from preclinical, initial, interim, preliminary, expected or prior clinical trial results; negative impacts of health emergencies, economic instability or international conflicts on ORIC’s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC’s license and collaboration agreements or its clinical trial collaboration and supply agreements; the potential market for ORIC’s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC’s reliance on third parties, including contract manufacturers and contract research organizations; ORIC’s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in ORIC’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on November 16, 2026, and ORIC’s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

 

Contact:

Dominic Piscitelli, Chief Financial Officer

dominic.piscitelli@oricpharma.com

info@oricpharma.com

 

All registered trademarks are the property of their respective owners.

 

 

 

 


 

 

 

ORIC PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEETS

(in thousands)

 

 

September 30, 2026

 

 

December 31, 2025

 

 

(unaudited)

 

 

 

 

Assets

 

Current assets:

 

 

 

 

 

Cash, cash equivalents and short-term investments

$

261,376

 

 

$

281,488

 

Prepaid expenses and other current assets

 

13,375

 

 

 

6,978

 

Total current assets

 

274,751

 

 

 

288,466

 

 

 

 

 

 

Long-term investments

 

83,986

 

 

 

110,762

 

Property and equipment, net

 

2,085

 

 

 

2,415

 

Other assets

 

6,064

 

 

 

7,247

 

Total assets

$

366,886

 

 

$

408,890

 

 

 

 

 

Liabilities and Stockholders' Equity

 

Current liabilities:

 

 

 

 

 

Accounts payable

$

2,151

 

 

$

3,824

 

Accrued liabilities

 

22,625

 

 

 

16,593

 

Total current liabilities

 

24,776

 

 

 

20,417

 

 

 

 

 

 

Other long-term liabilities

 

2,607

 

 

 

4,111

 

Total liabilities

 

27,383

 

 

 

24,528

 

 

 

 

 

 

Total stockholders' equity

 

339,503

 

 

 

384,362

 

Total liabilities and stockholders' equity

$

366,886

 

 

$

408,890

 

 

 

 

 

 

 

 

 

 


 

 

 

ORIC PHARMACEUTICALS, INC.

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(in thousands, except share and per share amounts)

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development

$

43,358

 

 

$

28,773

 

 

$

111,091

 

 

$

83,962

 

General and administrative

 

8,193

 

 

 

7,898

 

 

 

25,375

 

 

 

24,491

 

Total operating expenses

 

51,551

 

 

 

36,671

 

 

 

136,466

 

 

 

108,453

 

Loss from operations

 

(51,551

)

 

 

(36,671

)

 

 

(136,466

)

 

 

(108,453

)

 

 

 

 

 

 

 

 

 

 

 

Other income, net

 

3,475

 

 

 

4,084

 

 

 

11,131

 

 

 

9,490

 

Net loss

$

(48,076

)

 

$

(32,587

)

 

$

(125,335

)

 

$

(98,963

)

Other comprehensive (loss) gain:

 

 

 

 

 

 

 

 

 

 

 

 Unrealized (loss) gain on investments

 

(673

)

 

 

428

 

 

 

(2,477

)

 

 

236

 

Comprehensive loss

$

(48,749

)

 

$

(32,159

)

 

$

(127,812

)

 

$

(98,727

)

Net loss per share, basic and diluted

$

(0.44

)

 

$

(0.33

)

 

$

(1.17

)

 

$

(1.20

)

Weighted-average shares outstanding, basic and diluted

 

108,178,078

 

 

 

98,953,331

 

 

 

107,230,989

 

 

 

82,808,969

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Filing Exhibits & Attachments

2 documents

Keep reading